{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:47:34Z","timestamp":1794685654372,"version":"4.9.1"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca corrente"],"award-info":[{"award-number":["Ricerca corrente"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Myostatin is a negative regulator of skeletal muscle growth secreted by skeletal myocytes. In the past years, myostatin inhibition sparked interest among the scientific community for its potential to enhance muscle growth and to reduce, or even prevent, muscle atrophy. These characteristics make it a promising target for the treatment of muscle atrophy in motor neuron diseases, namely, amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), which are rare neurological diseases, whereby the degeneration of motor neurons leads to progressive muscle loss and paralysis. These diseases carry a huge burden of morbidity and mortality but, despite this unfavorable scenario, several therapeutic advancements have been made in the past years. Indeed, a number of different curative therapies for SMA have been approved, leading to a revolution in the life expectancy and outcomes of SMA patients. Similarly, tofersen, an antisense oligonucleotide, is now undergoing clinical trial phase for use in ALS patients carrying the SOD1 mutation. However, these therapies are not able to completely halt or reverse progression of muscle damage. Recently, a trial evaluating apitegromab, a myostatin inhibitor, in SMA patients was started, following positive results from preclinical studies. In this context, myostatin inhibition could represent a useful strategy to tackle motor symptoms in these patients. The aim of this review is to describe the myostatin pathway and its role in motor neuron diseases, and to summarize and critically discuss preclinical and clinical studies of myostatin inhibitors in SMA and ALS. Then, we will highlight promises and pitfalls related to the use of myostatin inhibitors in the human setting, to aid the scientific community in the development of future clinical trials.<\/jats:p>","DOI":"10.1007\/s00018-022-04408-w","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:05:21Z","timestamp":1655816721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Inhibition of myostatin and related signaling pathways for the treatment of muscle atrophy in motor neuron diseases"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0797-8282","authenticated-orcid":false,"given":"Elena","family":"Abati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Manini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Pietro","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"4408_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E (2011) Spinal muscular atrophy. Orphanet J Rare Dis 6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71","journal-title":"Orphanet J Rare Dis"},{"key":"4408_CR2","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3:17071. https:\/\/doi.org\/10.1038\/nrdp.2017.71","journal-title":"Nat Rev Dis Primers"},{"key":"4408_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000351153","volume":"41","author":"A Chi\u00f2","year":"2013","unstructured":"Chi\u00f2 A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118\u2013130. https:\/\/doi.org\/10.1159\/000351153","journal-title":"Neuroepidemiology"},{"key":"4408_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728222.2020.1738390","volume":"24","author":"E Abati","year":"2020","unstructured":"Abati E, Bresolin N, Comi G, Corti S (2020) Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). Expert Opin Ther Targets 24:295\u2013310. https:\/\/doi.org\/10.1080\/14728222.2020.1738390","journal-title":"Expert Opin Ther Targets"},{"key":"4408_CR5","doi-asserted-by":"publisher","first-page":"6703","DOI":"10.1007\/s12035-019-1554-x","volume":"56","author":"E Abati","year":"2019","unstructured":"Abati E, Bresolin N, Comi G, Corti S (2019) Advances, challenges, and perspectives in translational stem cell therapy for amyotrophic lateral sclerosis. Mol Neurobiol 56:6703\u20136715. https:\/\/doi.org\/10.1007\/s12035-019-1554-x","journal-title":"Mol Neurobiol"},{"key":"4408_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMOA2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, Cudkowicz M, Shaw PJ et al (2020) Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383:109\u2013119. https:\/\/doi.org\/10.1056\/NEJMOA2003715","journal-title":"N Engl J Med"},{"key":"4408_CR7","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1007\/S00018-018-2849-1","volume":"75","author":"H Chaytow","year":"2018","unstructured":"Chaytow H, Huang YT, Gillingwater TH, Faller KME (2018) The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci 75:3877\u20133894. https:\/\/doi.org\/10.1007\/S00018-018-2849-1","journal-title":"Cell Mol Life Sci"},{"key":"4408_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.MOLMED.2012.11.002","volume":"19","author":"G Hamilton","year":"2013","unstructured":"Hamilton G, Gillingwater TH (2013) Spinal muscular atrophy: going beyond the motor neuron. Trends Mol Med 19:40\u201350. https:\/\/doi.org\/10.1016\/J.MOLMED.2012.11.002","journal-title":"Trends Mol Med"},{"key":"4408_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/J.PEDIATRNEUROL.2020.01.003","volume":"109","author":"CJJ Yeo","year":"2020","unstructured":"Yeo CJJ, Darras BT (2020) Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol 109:12\u201319. https:\/\/doi.org\/10.1016\/J.PEDIATRNEUROL.2020.01.003","journal-title":"Pediatr Neurol"},{"key":"4408_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2020.104870","author":"E Abati","year":"2020","unstructured":"Abati E, Citterio G, Bresolin N et al (2020) Glial cells involvement in spinal muscular atrophy: could SMA be a neuroinflammatory disease? Neurobiol Dis. https:\/\/doi.org\/10.1016\/J.NBD.2020.104870","journal-title":"Neurobiol Dis"},{"key":"4408_CR11","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96:6307\u20136311. https:\/\/doi.org\/10.1073\/pnas.96.11.6307","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/J.BBAGRM.2016.12.008","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN (2017) Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech 1860:299\u2013315. https:\/\/doi.org\/10.1016\/J.BBAGRM.2016.12.008","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"4408_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldk\u00f6tter","year":"2002","unstructured":"Feldk\u00f6tter M, Schwarzer V, Wirth R et al (2002) Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 70:358\u2013368. https:\/\/doi.org\/10.1086\/338627","journal-title":"Am J Hum Genet"},{"key":"4408_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST (2012) Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 11:443\u2013452. https:\/\/doi.org\/10.1016\/S1474-4422(12)70061-3","journal-title":"Lancet Neurol"},{"key":"4408_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155\u2013165. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3","journal-title":"Cell"},{"key":"4408_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/J.NCL.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT (2015) Spinal muscular atrophy. Neurol Clin 33:831. https:\/\/doi.org\/10.1016\/J.NCL.2015.07.004","journal-title":"Neurol Clin"},{"key":"4408_CR17","volume-title":"FDA approves first drug for spinal muscular atrophy","author":"US Food and Drug Administration","year":"2016","unstructured":"US Food and Drug Administration (2016) FDA approves first drug for spinal muscular atrophy. US Food and Drug Administration US Food and Drug Administration, Rome"},{"key":"4408_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM (2019) Onasemnogene abeparvovec: first global approval. Drugs 79:1255\u20131262. https:\/\/doi.org\/10.1007\/s40265-019-01162-5","journal-title":"Drugs"},{"key":"4408_CR19","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMOA2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW et al (2021) Risdiplam in type 1 spinal muscular atrophy. N Engl J Med 384:915\u2013923. https:\/\/doi.org\/10.1056\/NEJMOA2009965","journal-title":"N Engl J Med"},{"key":"4408_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/387083A0","volume":"387","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83\u201390. https:\/\/doi.org\/10.1038\/387083A0","journal-title":"Nature"},{"key":"4408_CR21","doi-asserted-by":"publisher","first-page":"12457","DOI":"10.1073\/PNAS.94.23.12457","volume":"94","author":"AC McPherron","year":"1997","unstructured":"McPherron AC, Lee SJ (1997) Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94:12457\u201312461. https:\/\/doi.org\/10.1073\/PNAS.94.23.12457","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1101\/GR.7.9.910","volume":"7","author":"R Kambadur","year":"1997","unstructured":"Kambadur R, Sharma M, Smith TPL, Bass JJ (1997) Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 7:910\u2013916. https:\/\/doi.org\/10.1101\/GR.7.9.910","journal-title":"Genome Res"},{"key":"4408_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/NG1810","volume":"38","author":"A Clop","year":"2006","unstructured":"Clop A, Marcq F, Takeda H et al (2006) A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38:813\u2013818. https:\/\/doi.org\/10.1038\/NG1810","journal-title":"Nat Genet"},{"key":"4408_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1371\/JOURNAL.PGEN.0030079","volume":"3","author":"DS Mosher","year":"2007","unstructured":"Mosher DS, Quignon P, Bustamante CD et al (2007) A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 3:779\u2013786. https:\/\/doi.org\/10.1371\/JOURNAL.PGEN.0030079","journal-title":"PLoS Genet"},{"key":"4408_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/SREP25029","author":"Q Lv","year":"2016","unstructured":"Lv Q, Yuan L, Deng J et al (2016) Efficient generation of myostatin gene mutated rabbit by CRISPR\/Cas9. Sci Rep. https:\/\/doi.org\/10.1038\/SREP25029","journal-title":"Sci Rep"},{"key":"4408_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/J.BBRC.2016.06.030","volume":"477","author":"H Gu","year":"2016","unstructured":"Gu H, Cao Y, Qiu B et al (2016) Establishment and phenotypic analysis of an Mstn knockout rat. Biochem Biophys Res Commun 477:115\u2013122. https:\/\/doi.org\/10.1016\/J.BBRC.2016.06.030","journal-title":"Biochem Biophys Res Commun"},{"key":"4408_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/S11248-017-0044-Z","volume":"26","author":"K Wang","year":"2017","unstructured":"Wang K, Tang X, Xie Z et al (2017) CRISPR\/Cas9-mediated knockout of myostatin in Chinese indigenous Erhualian pigs. Transgenic Res 26:799\u2013805. https:\/\/doi.org\/10.1007\/S11248-017-0044-Z","journal-title":"Transgenic Res"},{"key":"4408_CR28","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20180742","author":"Z He","year":"2018","unstructured":"He Z, Zhang T, Jiang L et al (2018) Use of CRISPR\/Cas9 technology efficiently targetted goat myostatin through zygotes microinjection resulting in double-muscled phenotype in goats. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20180742"},{"key":"4408_CR29","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/nejmoa040933","volume":"350","author":"M Schuelke","year":"2004","unstructured":"Schuelke M, Wagner KR, Stolz LE et al (2004) Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682\u20132688. https:\/\/doi.org\/10.1056\/nejmoa040933","journal-title":"N Engl J Med"},{"key":"4408_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/J.RVSC.2007.09.014","volume":"85","author":"NR Sundaresan","year":"2008","unstructured":"Sundaresan NR, Saxena VK, Singh R et al (2008) Expression profile of myostatin mRNA during the embryonic organogenesis of domestic chicken (Gallus domesticus). Res Vet Sci 85:86\u201391. https:\/\/doi.org\/10.1016\/J.RVSC.2007.09.014","journal-title":"Res Vet Sci"},{"key":"4408_CR31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.14670\/HH-11-631","volume":"30","author":"H Takada","year":"2015","unstructured":"Takada H, Miwa Y, Sato I (2015) Expression of myostatin in early postnatal mouse masseter and rectus femoris muscles. Histol Histopathol 30:1353\u20131365. https:\/\/doi.org\/10.14670\/HH-11-631","journal-title":"Histol Histopathol"},{"key":"4408_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-981-13-1435-3_8","volume":"1088","author":"WMH Hoogaars","year":"2018","unstructured":"Hoogaars WMH, Jaspers RT (2018) Past, present, and future perspective of targeting myostatin and related signaling pathways to counteract muscle atrophy. Adv Exp Med Biol 1088:153\u2013206. https:\/\/doi.org\/10.1007\/978-981-13-1435-3_8","journal-title":"Adv Exp Med Biol"},{"key":"4408_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1206410109","author":"SJ Lee","year":"2012","unstructured":"Lee SJ, Huynh TV, Lee YS et al (2012) Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin\/activin signaling pathway. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/PNAS.1206410109","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.15252\/EMBJ.201797931","volume":"37","author":"VQ Le","year":"2018","unstructured":"Le VQ, Iacob RE, Tian Y et al (2018) Tolloid cleavage activates latent GDF8 by priming the pro-complex for dissociation. EMBO J 37:384\u2013397. https:\/\/doi.org\/10.15252\/EMBJ.201797931","journal-title":"EMBO J"},{"key":"4408_CR35","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/J.BIOCEL.2013.05.019","volume":"45","author":"HQ Han","year":"2013","unstructured":"Han HQ, Zhou X, Mitch WE, Goldberg AL (2013) Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol 45:2333\u20132347. https:\/\/doi.org\/10.1016\/J.BIOCEL.2013.05.019","journal-title":"Int J Biochem Cell Biol"},{"key":"4408_CR36","doi-asserted-by":"publisher","first-page":"15842","DOI":"10.1073\/PNAS.2534946100","volume":"100","author":"NM Wolfman","year":"2003","unstructured":"Wolfman NM, McPherron AC, Pappano WN et al (2003) Activation of latent myostatin by the BMP-1\/tolloid family of metalloproteinases. Proc Natl Acad Sci USA 100:15842\u201315846. https:\/\/doi.org\/10.1073\/PNAS.2534946100","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR37","doi-asserted-by":"publisher","first-page":"40735","DOI":"10.1074\/JBC.M206379200","volume":"277","author":"JJ Hill","year":"2002","unstructured":"Hill JJ, Davies MV, Pearson AA et al (2002) The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 277:40735\u201340741. https:\/\/doi.org\/10.1074\/JBC.M206379200","journal-title":"J Biol Chem"},{"key":"4408_CR38","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1126\/SCIENCE.1069525","volume":"296","author":"TA Zimmers","year":"2002","unstructured":"Zimmers TA, Davies MV, Koniaris LG et al (2002) Induction of cachexia in mice by systemically administered myostatin. Science 296:1486\u20131488. https:\/\/doi.org\/10.1126\/SCIENCE.1069525","journal-title":"Science"},{"key":"4408_CR39","doi-asserted-by":"publisher","first-page":"9306","DOI":"10.1073\/PNAS.151270098","volume":"98","author":"SJ Lee","year":"2001","unstructured":"Lee SJ, McPherron AC (2001) Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98:9306\u20139311. https:\/\/doi.org\/10.1073\/PNAS.151270098","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR40","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1006\/DBIO.1998.9191","volume":"208","author":"LW Gamer","year":"1999","unstructured":"Gamer LW, Wolfman NM, Celeste AJ et al (1999) A novel BMP expressed in developing mouse limb, spinal cord, and tail bud is a potent mesoderm inducer in Xenopus embryos. Dev Biol 208:222\u2013232. https:\/\/doi.org\/10.1006\/DBIO.1998.9191","journal-title":"Dev Biol"},{"key":"4408_CR41","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1073\/PNAS.95.16.9337","volume":"95","author":"SI Iemura","year":"1998","unstructured":"Iemura SI, Yamamoto TS, Takagi C et al (1998) Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci U S A 95:9337\u20139342. https:\/\/doi.org\/10.1073\/PNAS.95.16.9337","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4408_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0925-4773(97)00673-4","volume":"63","author":"A Fainsod","year":"1997","unstructured":"Fainsod A, Dei\u00dfler K, Yelin R et al (1997) The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. Mech Dev 63:39\u201350. https:\/\/doi.org\/10.1016\/S0925-4773(97)00673-4","journal-title":"Mech Dev"},{"key":"4408_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1083\/JCB.130.1.217","volume":"130","author":"H Yamashita","year":"1995","unstructured":"Yamashita H, ten Dijke P, Huylebroeck D et al (1995) Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 130:217\u2013226. https:\/\/doi.org\/10.1083\/JCB.130.1.217","journal-title":"J Cell Biol"},{"key":"4408_CR44","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1126\/SCIENCE.2106159","volume":"247","author":"T Nakamura","year":"1990","unstructured":"Nakamura T, Takio K, Eto Y et al (1990) Activin-binding protein from rat ovary is follistatin. Science 247:836\u2013838. https:\/\/doi.org\/10.1126\/SCIENCE.2106159","journal-title":"Science"},{"key":"4408_CR45","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/J.YEXCR.2006.04.012","volume":"312","author":"JE Dominique","year":"2006","unstructured":"Dominique JE, G\u00e9rard C (2006) Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res 312:2401\u20132414. https:\/\/doi.org\/10.1016\/J.YEXCR.2006.04.012","journal-title":"Exp Cell Res"},{"key":"4408_CR46","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1007\/S00018-014-1689-X","volume":"71","author":"J Rodriguez","year":"2014","unstructured":"Rodriguez J, Vernus B, Chelh I et al (2014) Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell Mol Life Sci 71:4361\u20134371. https:\/\/doi.org\/10.1007\/S00018-014-1689-X","journal-title":"Cell Mol Life Sci"},{"key":"4408_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/S12020-012-9751-7","volume":"43","author":"JP Gumucio","year":"2013","unstructured":"Gumucio JP, Mendias CL (2013) Atrogin-1, MuRF-1, and sarcopenia. Endocrine 43:12\u201321. https:\/\/doi.org\/10.1007\/S12020-012-9751-7","journal-title":"Endocrine"},{"key":"4408_CR48","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1152\/AJPCELL.00104.2009\/SUPPL_FILE\/SUPPLEMENTAL","volume":"296","author":"R Sartori","year":"2009","unstructured":"Sartori R, Milan G, Patron M et al (2009) Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Phys Cell Physiol 296:1248\u20131257. https:\/\/doi.org\/10.1152\/AJPCELL.00104.2009\/SUPPL_FILE\/SUPPLEMENTAL","journal-title":"Am J Phys Cell Physiol"},{"key":"4408_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/NCOMMS15153","author":"E Latres","year":"2017","unstructured":"Latres E, Mastaitis J, Fury W et al (2017) Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. https:\/\/doi.org\/10.1038\/NCOMMS15153","journal-title":"Nat Commun"},{"key":"4408_CR50","doi-asserted-by":"publisher","first-page":"E5266","DOI":"10.1073\/PNAS.1620013114","volume":"114","author":"JL Chen","year":"2017","unstructured":"Chen JL, Walton KL, Hagg A et al (2017) Specific targeting of TGF-\u03b2 family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc Natl Acad Sci USA 114:E5266\u2013E5275. https:\/\/doi.org\/10.1073\/PNAS.1620013114","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0000789","author":"SJ Lee","year":"2007","unstructured":"Lee SJ (2007) Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0000789","journal-title":"PLoS ONE"},{"key":"4408_CR52","doi-asserted-by":"publisher","first-page":"18117","DOI":"10.1073\/PNAS.0505996102","volume":"102","author":"SJ Lee","year":"2005","unstructured":"Lee SJ, Reed LA, Davies M, v, et al (2005) Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci U S A 102:18117\u201318122. https:\/\/doi.org\/10.1073\/PNAS.0505996102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4408_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.MAD.2017.04.009","volume":"164","author":"X Fan","year":"2017","unstructured":"Fan X, Gaur U, Sun L et al (2017) The Growth Differentiation Factor 11 (GDF11) and Myostatin (MSTN) in tissue specific aging. Mech Ageing Dev 164:108\u2013112. https:\/\/doi.org\/10.1016\/J.MAD.2017.04.009","journal-title":"Mech Ageing Dev"},{"key":"4408_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0925-4773(98)00205-6","volume":"80","author":"M Nakashima","year":"1999","unstructured":"Nakashima M, Toyono T, Akamine A, Joyner A (1999) Expression of growth\/differentiation factor 11, a new member of the BMP\/TGFbeta superfamily during mouse embryogenesis. Mech Dev 80:185\u2013189. https:\/\/doi.org\/10.1016\/S0925-4773(98)00205-6","journal-title":"Mech Dev"},{"key":"4408_CR55","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/J.CMET.2016.05.023","volume":"23","author":"MJ Schafer","year":"2016","unstructured":"Schafer MJ, Atkinson EJ, Vanderboom PM et al (2016) Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab 23:1207\u20131215. https:\/\/doi.org\/10.1016\/J.CMET.2016.05.023","journal-title":"Cell Metab"},{"key":"4408_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/S13395-015-0047-5","author":"HR Bergen","year":"2015","unstructured":"Bergen HR, Farr JN, Vanderboom PM et al (2015) Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle. https:\/\/doi.org\/10.1186\/S13395-015-0047-5","journal-title":"Skelet Muscle"},{"key":"4408_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/S12877-018-0888-Y","author":"E Fife","year":"2018","unstructured":"Fife E, Kostka J, Kroc \u0141 et al (2018) Relationship of muscle function to circulating myostatin, follistatin and GDF11 in older women and men. BMC Geriatr. https:\/\/doi.org\/10.1186\/S12877-018-0888-Y","journal-title":"BMC Geriatr"},{"key":"4408_CR58","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0531-5565(01)00117-6","volume":"36","author":"A Baccarelli","year":"2001","unstructured":"Baccarelli A, Morpurgo PS, Corsi A et al (2001) Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects. Exp Gerontol 36:1403\u20131412. https:\/\/doi.org\/10.1016\/S0531-5565(01)00117-6","journal-title":"Exp Gerontol"},{"key":"4408_CR59","first-page":"672","volume":"5","author":"DS Willoughby","year":"2006","unstructured":"Willoughby DS, Wilborn CD (2006) Estradiol in females may negate skeletal muscle myostatin mrna expression and serum myostatin propeptide levels after eccentric muscle contractions. J Sports Sci Med 5:672","journal-title":"J Sports Sci Med"},{"key":"4408_CR60","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.MCE.2008.12.019","volume":"302","author":"KM Lakshman","year":"2009","unstructured":"Lakshman KM, Bhasin S, Corcoran C et al (2009) Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol Cell Endocrinol 302:26\u201332. https:\/\/doi.org\/10.1016\/J.MCE.2008.12.019","journal-title":"Mol Cell Endocrinol"},{"key":"4408_CR61","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1210\/JC.2013-2835","volume":"99","author":"GI Smith","year":"2014","unstructured":"Smith GI, Yoshino J, Reeds DN et al (2014) Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Metab 99:256. https:\/\/doi.org\/10.1210\/JC.2013-2835","journal-title":"J Clin Endocrinol Metab"},{"key":"4408_CR62","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1582-4934.2011.01498.x","volume":"16","author":"S Salani","year":"2012","unstructured":"Salani S, Donadoni C, Rizzo F et al (2012) Generation of skeletal muscle cells from embryonic and induced pluripotent stem cells as an in vitro model and for therapy of muscular dystrophies. J Cell Mol Med 16:1353\u20131364. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01498.x","journal-title":"J Cell Mol Med"},{"key":"4408_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22179630","author":"E Abati","year":"2021","unstructured":"Abati E, Sclarandi E, Comipietro, G et al (2021) Perspectives on hiPSC-derived muscle cells as drug discovery models for muscular dystrophies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS22179630","journal-title":"Int J Mol Sci"},{"key":"4408_CR64","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0014-4827(03)00074-0","volume":"286","author":"D Joulia","year":"2003","unstructured":"Joulia D, Bernardi H, Garandel V et al (2003) Mechanisms involved in the inhibition of myoblast proliferation and differentiation by myostatin. Exp Cell Res 286:263\u2013275. https:\/\/doi.org\/10.1016\/S0014-4827(03)00074-0","journal-title":"Exp Cell Res"},{"key":"4408_CR65","doi-asserted-by":"publisher","first-page":"49831","DOI":"10.1074\/JBC.M204291200","volume":"277","author":"B Langley","year":"2002","unstructured":"Langley B, Thomas M, Bishop A et al (2002) Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 277:49831\u201349840. https:\/\/doi.org\/10.1074\/JBC.M204291200","journal-title":"J Biol Chem"},{"key":"4408_CR66","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1128\/MCB.18.1.546","volume":"18","author":"V Duli\u0107","year":"1998","unstructured":"Duli\u0107 V, Stein GH, Far DF, Reed SI (1998) Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2\/M-phase transition. Mol Cell Biol 18:546\u2013557. https:\/\/doi.org\/10.1128\/MCB.18.1.546","journal-title":"Mol Cell Biol"},{"key":"4408_CR67","doi-asserted-by":"publisher","first-page":"40235","DOI":"10.1074\/JBC.M004356200","volume":"275","author":"M Thomas","year":"2000","unstructured":"Thomas M, Langley B, Berry C et al (2000) Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 275:40235\u201340243. https:\/\/doi.org\/10.1074\/JBC.M004356200","journal-title":"J Biol Chem"},{"key":"4408_CR68","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1006\/BBRC.2000.4159","volume":"280","author":"R R\u00edos","year":"2001","unstructured":"R\u00edos R, Carneiro I, Arce VM, Devesa J (2001) Myostatin regulates cell survival during C2C12 myogenesis. Biochem Biophys Res Commun 280:561\u2013566. https:\/\/doi.org\/10.1006\/BBRC.2000.4159","journal-title":"Biochem Biophys Res Commun"},{"key":"4408_CR69","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1073\/PNAS.1525795113","volume":"113","author":"JPG Camporez","year":"2016","unstructured":"Camporez JPG, Petersen MC, Abudukadier A et al (2016) Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice. Proc Natl Acad Sci USA 113:2212\u20132217. https:\/\/doi.org\/10.1073\/PNAS.1525795113","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR70","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/IJO.2009.162","volume":"33","author":"I Akpan","year":"2009","unstructured":"Akpan I, Goncalves MD, Dhir R et al (2009) The effects of a soluble activin type IIB receptor on obesity and insulin sensitivity. Int J Obes (Lond) 33:1265\u20131273. https:\/\/doi.org\/10.1038\/IJO.2009.162","journal-title":"Int J Obes (Lond)"},{"key":"4408_CR71","doi-asserted-by":"publisher","DOI":"10.1152\/AJPENDO.00586.2013","author":"ME Cleasby","year":"2014","unstructured":"Cleasby ME, Jarmin S, Eilers W et al (2014) Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal. Am J Physiol Endocrinol Metab. https:\/\/doi.org\/10.1152\/AJPENDO.00586.2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4408_CR72","doi-asserted-by":"publisher","first-page":"4937","DOI":"10.1371\/JOURNAL.PONE.0004937","volume":"4","author":"T Guo","year":"2009","unstructured":"Guo T, Jou W, Chanturiya T et al (2009) Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS ONE 4:4937. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0004937","journal-title":"PLoS ONE"},{"key":"4408_CR73","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1210\/EN.2010-0134","volume":"151","author":"A Koncarevic","year":"2010","unstructured":"Koncarevic A, Cornwall-Brady M, Pullen A et al (2010) A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology 151:4289\u20134300. https:\/\/doi.org\/10.1210\/EN.2010-0134","journal-title":"Endocrinology"},{"key":"4408_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PONE.0012707","volume":"5","author":"MD Goncalves","year":"2010","unstructured":"Goncalves MD, Pistilli EE, Balduzzi A et al (2010) Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoS ONE 5:1\u201312. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0012707","journal-title":"PLoS ONE"},{"key":"4408_CR75","doi-asserted-by":"publisher","first-page":"30907","DOI":"10.1073\/PNAS.2019263117","volume":"117","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Lehar A, Liu Y et al (2020) Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A. Proc Natl Acad Sci USA 117:30907\u201330917. https:\/\/doi.org\/10.1073\/PNAS.2019263117","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR76","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/OBY.20117","volume":"21","author":"M Braga","year":"2013","unstructured":"Braga M, Pervin S, Norris K et al (2013) Inhibition of in vitro and in vivo brown fat differentiation program by myostatin. Obesity (Silver Spring) 21:1180\u20131188. https:\/\/doi.org\/10.1002\/OBY.20117","journal-title":"Obesity (Silver Spring)"},{"key":"4408_CR77","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1128\/MCB.06575-11","volume":"32","author":"B Fournier","year":"2012","unstructured":"Fournier B, Murray B, Gutzwiller S et al (2012) Blockade of the activin receptor IIb activates functional brown adipogenesis and thermogenesis by inducing mitochondrial oxidative metabolism. Mol Cell Biol 32:2871\u20132879. https:\/\/doi.org\/10.1128\/MCB.06575-11","journal-title":"Mol Cell Biol"},{"key":"4408_CR78","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/GERONA\/GLP068","volume":"64","author":"NK LeBrasseur","year":"2009","unstructured":"LeBrasseur NK, Schelhorn TM, Bernardo BL et al (2009) Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A Biol Sci Med Sci 64:940\u2013948. https:\/\/doi.org\/10.1093\/GERONA\/GLP068","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"4408_CR79","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1210\/EN.2005-0362","volume":"146","author":"JN Artaza","year":"2005","unstructured":"Artaza JN, Bhasin S, Magee TR et al (2005) Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1\/2) mesenchymal multipotent cells. Endocrinology 146:3547\u20133557. https:\/\/doi.org\/10.1210\/EN.2005-0362","journal-title":"Endocrinology"},{"key":"4408_CR80","doi-asserted-by":"publisher","first-page":"7230","DOI":"10.1128\/MCB.23.20.7230-7242.2003","volume":"23","author":"A Rebbapragada","year":"2003","unstructured":"Rebbapragada A, Benchabane H, Wrana JL et al (2003) Myostatin signals through a transforming growth factor \u03b2-like signaling pathway to block adipogenesis. Mol Cell Biol 23:7230. https:\/\/doi.org\/10.1128\/MCB.23.20.7230-7242.2003","journal-title":"Mol Cell Biol"},{"key":"4408_CR81","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3109\/17482968.2011.560946","volume":"12","author":"A Shtilbans","year":"2011","unstructured":"Shtilbans A, Choi SG, Fowkes ME et al (2011) Differential gene expression in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12:250\u2013256. https:\/\/doi.org\/10.3109\/17482968.2011.560946","journal-title":"Amyotroph Lateral Scler"},{"key":"4408_CR82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000329723","volume":"9","author":"PF Pradat","year":"2012","unstructured":"Pradat PF, Dubourg O, de Tapia M et al (2012) Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. Neurodegener Dis 9:38\u201352. https:\/\/doi.org\/10.1159\/000329723","journal-title":"Neurodegener Dis"},{"key":"4408_CR83","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/S10571-014-0029-X","volume":"34","author":"GP de Oliveira","year":"2014","unstructured":"de Oliveira GP, Maximino JR, Maschietto M et al (2014) Early gene expression changes in skeletal muscle from SOD1(G93A) amyotrophic lateral sclerosis animal model. Cell Mol Neurobiol 34:451\u2013462. https:\/\/doi.org\/10.1007\/S10571-014-0029-X","journal-title":"Cell Mol Neurobiol"},{"key":"4408_CR84","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/PHYSIOLGENOMICS.00017.2007\/SUPPL_FILE\/SUPPTEXTREVII.PDF","volume":"32","author":"JL Gonzalez De Aguilar","year":"2008","unstructured":"Gonzalez De Aguilar JL, Niederhauser-Wiederkehr C, Halter B et al (2008) Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. Physiol Genom 32:207\u2013218. https:\/\/doi.org\/10.1152\/PHYSIOLGENOMICS.00017.2007\/SUPPL_FILE\/SUPPTEXTREVII.PDF","journal-title":"Physiol Genom"},{"key":"4408_CR85","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5414\/NP300889","volume":"35","author":"E Tasca","year":"2016","unstructured":"Tasca E, Pegoraro V, Merico A, Angelini C (2016) Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin Neuropathol 35:22\u201330. https:\/\/doi.org\/10.5414\/NP300889","journal-title":"Clin Neuropathol"},{"key":"4408_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-017-01486-4","author":"V Mariot","year":"2017","unstructured":"Mariot V, Joubert R, Hourd\u00e9 C et al (2017) Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. https:\/\/doi.org\/10.1038\/S41467-017-01486-4","journal-title":"Nat Commun"},{"key":"4408_CR87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.149446","author":"KE Meijboom","year":"2021","unstructured":"Meijboom KE, Volpato V, Monz\u00f3n-Sandoval J et al (2021) Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy. JCI Insight. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.149446","journal-title":"JCI Insight"},{"key":"4408_CR88","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/S00415-016-8379-6","volume":"264","author":"PM Burch","year":"2017","unstructured":"Burch PM, Pogoryelova O, Palandra J et al (2017) Reduced serum myostatin concentrations associated with genetic muscle disease progression. J Neurol 264:541\u2013553. https:\/\/doi.org\/10.1007\/S00415-016-8379-6","journal-title":"J Neurol"},{"key":"4408_CR89","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/HMG\/DDN426","volume":"18","author":"FF Rose","year":"2009","unstructured":"Rose FF, Mattis VB, Rindt H, Lorson CL (2009) Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum Mol Genet 18:997\u20131005. https:\/\/doi.org\/10.1093\/HMG\/DDN426","journal-title":"Hum Mol Genet"},{"key":"4408_CR90","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/J.NMD.2011.10.012","volume":"22","author":"H Rindt","year":"2012","unstructured":"Rindt H, Buckley DM, Vale SM et al (2012) Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Neuromuscul Disord 22:277\u2013285. https:\/\/doi.org\/10.1016\/J.NMD.2011.10.012","journal-title":"Neuromuscul Disord"},{"key":"4408_CR91","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1093\/HMG\/DDP253","volume":"18","author":"CJ Sumner","year":"2009","unstructured":"Sumner CJ, Wee CD, Warsing LC et al (2009) Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet 18:3145\u20133152. https:\/\/doi.org\/10.1093\/HMG\/DDP253","journal-title":"Hum Mol Genet"},{"key":"4408_CR92","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1093\/HMG\/DDQ329","volume":"19","author":"M Shababi","year":"2010","unstructured":"Shababi M, Habibi J, Yang HT et al (2010) Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum Mol Genet 19:4059\u20134071. https:\/\/doi.org\/10.1093\/HMG\/DDQ329","journal-title":"Hum Mol Genet"},{"key":"4408_CR93","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/HMG\/DDV629","volume":"25","author":"Z Feng","year":"2016","unstructured":"Feng Z, Ling KKY, Zhao X et al (2016) Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset. Hum Mol Genet 25:964\u2013975. https:\/\/doi.org\/10.1093\/HMG\/DDV629","journal-title":"Hum Mol Genet"},{"key":"4408_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0166803","author":"M Liu","year":"2016","unstructured":"Liu M, Hammers DW, Barton ER, Sweeney HL (2016) Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0166803","journal-title":"PLoS ONE"},{"key":"4408_CR95","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/JCSM.12542","volume":"11","author":"H Zhou","year":"2020","unstructured":"Zhou H, Meng J, Malerba A et al (2020) Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle 11:768\u2013782. https:\/\/doi.org\/10.1002\/JCSM.12542","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"4408_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-018-20524-9","author":"M Pirruccello-Straub","year":"2018","unstructured":"Pirruccello-Straub M, Jackson J, Wawersik S et al (2018) Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-018-20524-9","journal-title":"Sci Rep"},{"key":"4408_CR97","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/HMG\/DDY382","volume":"28","author":"KK Long","year":"2019","unstructured":"Long KK, O\u2019Shea KM, Khairallah RJ et al (2019) Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy. Hum Mol Genet 28:1076\u20131089. https:\/\/doi.org\/10.1093\/HMG\/DDY382","journal-title":"Hum Mol Genet"},{"key":"4408_CR98","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/J.NBD.2006.05.009","volume":"23","author":"ELF Holzbaur","year":"2006","unstructured":"Holzbaur ELF, Howland DS, Weber N et al (2006) Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol Dis 23:697\u2013707. https:\/\/doi.org\/10.1016\/J.NBD.2006.05.009","journal-title":"Neurobiol Dis"},{"key":"4408_CR99","doi-asserted-by":"publisher","first-page":"19546","DOI":"10.1073\/PNAS.0609411103","volume":"103","author":"TM Miller","year":"2006","unstructured":"Miller TM, Kim SH, Yamanaka K et al (2006) Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 103:19546\u201319551. https:\/\/doi.org\/10.1073\/PNAS.0609411103","journal-title":"Proc Natl Acad Sci USA"},{"key":"4408_CR100","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/J.EXPNEUROL.2009.02.017","volume":"217","author":"BM Morrison","year":"2009","unstructured":"Morrison BM, Lachey JL, Warsing LC et al (2009) A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 217:258\u2013268. https:\/\/doi.org\/10.1016\/J.EXPNEUROL.2009.02.017","journal-title":"Exp Neurol"},{"key":"4408_CR101","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138634","author":"J Li","year":"2021","unstructured":"Li J, Fredericks M, Cannell M et al (2021) ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI138634","journal-title":"J Clin Invest"},{"key":"4408_CR102","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/JCSM.12331","volume":"9","author":"T Golan","year":"2018","unstructured":"Golan T, Geva R, Richards D et al (2018) LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. J Cachexia Sarcopenia Muscle 9:871\u2013879. https:\/\/doi.org\/10.1002\/JCSM.12331","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"4408_CR103","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ANA.21338","volume":"63","author":"KR Wagner","year":"2008","unstructured":"Wagner KR, Fleckenstein JL, Amato AA et al (2008) A phase I\/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561\u2013571. https:\/\/doi.org\/10.1002\/ANA.21338","journal-title":"Ann Neurol"},{"key":"4408_CR104","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/J.NMD.2020.05.002","volume":"30","author":"KR Wagner","year":"2020","unstructured":"Wagner KR, Abdel-Hamid HZ, Mah JK et al (2020) Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord 30:492\u2013502. https:\/\/doi.org\/10.1016\/J.NMD.2020.05.002","journal-title":"Neuromuscul Disord"},{"key":"4408_CR105","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","volume":"3","author":"C Becker","year":"2015","unstructured":"Becker C, Lord SR, Studenski SA et al (2015) Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol 3:948\u2013957. https:\/\/doi.org\/10.1016\/S2213-8587(15)00298-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4408_CR106","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/JGS.14927","volume":"65","author":"D Rooks","year":"2017","unstructured":"Rooks D, Praestgaard J, Hariry S et al (2017) Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc 65:1988\u20131995. https:\/\/doi.org\/10.1111\/JGS.14927","journal-title":"J Am Geriatr Soc"},{"key":"4408_CR107","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","volume":"18","author":"MG Hanna","year":"2019","unstructured":"Hanna MG, Badrising UA, Benveniste O et al (2019) Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol 18:834\u2013844. https:\/\/doi.org\/10.1016\/S1474-4422(19)30200-5","journal-title":"Lancet Neurol"},{"key":"4408_CR108","doi-asserted-by":"publisher","first-page":"62","DOI":"10.14283\/JFA.2016.81","volume":"5","author":"L Woodhouse","year":"2016","unstructured":"Woodhouse L, Gandhi R, Warden SJ et al (2016) A Phase 2 randomized study investigating the efficacy and safety of myostatin antibody LY2495655 versus placebo in patients undergoing elective total hip arthroplasty. J Frailty Aging 5:62\u201370. https:\/\/doi.org\/10.14283\/JFA.2016.81","journal-title":"J Frailty Aging"},{"key":"4408_CR109","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2020.33457","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R et al (2021) Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2020.33457","journal-title":"JAMA Netw Open"},{"key":"4408_CR110","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1007\/S12325-021-01757-Z","volume":"38","author":"D Barrett","year":"2021","unstructured":"Barrett D, Bilic S, Chyung Y et al (2021) A randomized phase 1 safety, pharmacokinetic and pharmacodynamic study of the novel myostatin inhibitor apitegromab (SRK-015): a potential treatment for spinal muscular atrophy. Adv Ther 38:3203\u20133222. https:\/\/doi.org\/10.1007\/S12325-021-01757-Z","journal-title":"Adv Ther"},{"key":"4408_CR111","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/J.NMD.2021.01.001","volume":"31","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Abdel-Hamid HZ, Mah JK et al (2021) Corrigendum to Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscul Disord 31:167\u2013168. https:\/\/doi.org\/10.1016\/J.NMD.2021.01.001","journal-title":"Neuromuscul Disord"},{"key":"4408_CR112","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","volume":"83","author":"AA Amato","year":"2014","unstructured":"Amato AA, Sivakumar K, Goyal N et al (2014) Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 83:2239\u20132246. https:\/\/doi.org\/10.1212\/WNL.0000000000001070","journal-title":"Neurology"},{"key":"4408_CR113","doi-asserted-by":"publisher","first-page":"e1595","DOI":"10.1212\/WNL.0000000000011626","volume":"96","author":"AA Amato","year":"2021","unstructured":"Amato AA, Hanna MG, Machado PM et al (2021) Efficacy and safety of bimagrumab in sporadic inclusion body myositis: long-term extension of RESILIENT. Neurology 96:e1595\u2013e1607. https:\/\/doi.org\/10.1212\/WNL.0000000000011626","journal-title":"Neurology"},{"key":"4408_CR114","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/MUS.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK et al (2017) Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial. Muscle Nerve 55:458\u2013464. https:\/\/doi.org\/10.1002\/MUS.25268","journal-title":"Muscle Nerve"},{"key":"4408_CR115","doi-asserted-by":"publisher","first-page":"e1971","DOI":"10.1212\/WNL.0000000000010417","volume":"95","author":"K Sivakumar","year":"2020","unstructured":"Sivakumar K, Cochrane TI, Sloth B et al (2020) Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis. Neurology 95:e1971\u2013e1978. https:\/\/doi.org\/10.1212\/WNL.0000000000010417","journal-title":"Neurology"},{"key":"4408_CR116","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","volume":"34","author":"E Lach-Trifilieff","year":"2014","unstructured":"Lach-Trifilieff E, Minetti GC, Sheppard K et al (2014) An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 34:606\u2013618. https:\/\/doi.org\/10.1128\/MCB.01307-13","journal-title":"Mol Cell Biol"},{"key":"4408_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/S13395-015-0060-8","author":"E Latres","year":"2015","unstructured":"Latres E, Pangilinan J, Miloscio L et al (2015) Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. https:\/\/doi.org\/10.1186\/S13395-015-0060-8","journal-title":"Skelet Muscle"},{"key":"4408_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/S13395-017-0141-Y","author":"st. Andre M, Johnson M, Bansal PN,","year":"2017","unstructured":"st. Andre M, Johnson M, Bansal PN, et al (2017) A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. https:\/\/doi.org\/10.1186\/S13395-017-0141-Y","journal-title":"Skelet Muscle"},{"key":"4408_CR119","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1164\/RCCM.201802-0286OC","volume":"199","author":"MI Polkey","year":"2019","unstructured":"Polkey MI, Praestgaard J, Berwick A et al (2019) Activin type II receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. a randomized trial. Am J Respir Crit Care Med 199:313\u2013320. https:\/\/doi.org\/10.1164\/RCCM.201802-0286OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4408_CR120","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1183\/09031936.00032510","volume":"36","author":"WDC Man","year":"2010","unstructured":"Man WDC, Natanek SA, Riddoch-Contreras J et al (2010) Quadriceps myostatin expression in COPD. Eur Respir J 36:686\u2013689. https:\/\/doi.org\/10.1183\/09031936.00032510","journal-title":"Eur Respir J"},{"key":"4408_CR121","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/JCMM.12390","volume":"19","author":"P Pomi\u00e8s","year":"2015","unstructured":"Pomi\u00e8s P, Rodriguez J, Blaqui\u00e8re M et al (2015) Reduced myotube diameter, atrophic signalling and elevated oxidative stress in cultured satellite cells from COPD patients. J Cell Mol Med 19:175\u2013186. https:\/\/doi.org\/10.1111\/JCMM.12390","journal-title":"J Cell Mol Med"},{"key":"4408_CR122","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1210\/JC.2014-4318","volume":"100","author":"A Loumaye","year":"2015","unstructured":"Loumaye A, de Barsy M, Nachit M et al (2015) Role of activin a and myostatin in human cancer cachexia. J Clin Endocrinol Metab 100:2030\u20132038. https:\/\/doi.org\/10.1210\/JC.2014-4318","journal-title":"J Clin Endocrinol Metab"},{"key":"4408_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/S13395-016-0098-2","author":"S Hatakeyama","year":"2016","unstructured":"Hatakeyama S, Summermatter S, Jourdain M et al (2016) ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skelet Muscle. https:\/\/doi.org\/10.1186\/S13395-016-0098-2","journal-title":"Skelet Muscle"},{"key":"4408_CR124","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/J.CELL.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou X, Wang JL, Lu J et al (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142:531\u2013543. https:\/\/doi.org\/10.1016\/J.CELL.2010.07.011","journal-title":"Cell"},{"key":"4408_CR125","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/1535-7163.MCT-14-0681","volume":"14","author":"RC Smith","year":"2015","unstructured":"Smith RC, Cramer MS, Mitchell PJ et al (2015) Myostatin neutralization results in preservation of muscle mass and strength in preclinical models of tumor-induced muscle wasting. Mol Cancer Ther 14:1661\u20131670. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0681","journal-title":"Mol Cancer Ther"},{"key":"4408_CR126","doi-asserted-by":"publisher","DOI":"10.1152\/AJPENDO.2001.281.6.E1128","author":"M Kun","year":"2001","unstructured":"Kun M, Mallidis C, Artaza J et al (2001) Characterization of 5\u2019-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab. https:\/\/doi.org\/10.1152\/AJPENDO.2001.281.6.E1128","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"4408_CR127","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/J.RVSC.2012.07.018","volume":"94","author":"J Qin","year":"2013","unstructured":"Qin J, Du R, Yang YQ et al (2013) Dexamethasone-induced skeletal muscle atrophy was associated with upregulation of myostatin promoter activity. Res Vet Sci 94:84\u201389. https:\/\/doi.org\/10.1016\/J.RVSC.2012.07.018","journal-title":"Res Vet Sci"},{"key":"4408_CR128","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1210\/EN.2006-0539","volume":"148","author":"H Gilson","year":"2007","unstructured":"Gilson H, Schakman O, Combaret L et al (2007) Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy. Endocrinology 148:452\u2013460. https:\/\/doi.org\/10.1210\/EN.2006-0539","journal-title":"Endocrinology"},{"key":"4408_CR129","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAU8680","author":"JD Roh","year":"2019","unstructured":"Roh JD, Hobson R, Chaudhari V et al (2019) Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAU8680","journal-title":"Sci Transl Med"},{"key":"4408_CR130","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.109.882068","volume":"121","author":"J Heineke","year":"2010","unstructured":"Heineke J, Auger-Messier M, Xu J et al (2010) Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 121:419\u2013425. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.882068","journal-title":"Circulation"},{"key":"4408_CR131","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/EURJHF\/HFQ039","volume":"12","author":"I George","year":"2010","unstructured":"George I, Bish LT, Kamalakkannan G et al (2010) Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail 12:444\u2013453. https:\/\/doi.org\/10.1093\/EURJHF\/HFQ039","journal-title":"Eur J Heart Fail"},{"key":"4408_CR132","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/JCSM.12205","volume":"8","author":"DS Rooks","year":"2017","unstructured":"Rooks DS, Laurent D, Praestgaard J et al (2017) Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J Cachexia Sarcopenia Muscle 8:727\u2013734. https:\/\/doi.org\/10.1002\/JCSM.12205","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"4408_CR133","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/JCSM.12639","volume":"11","author":"D Rooks","year":"2020","unstructured":"Rooks D, Petricoul O, Praestgaard J et al (2020) Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. J Cachexia Sarcopenia Muscle 11:1525\u20131534. https:\/\/doi.org\/10.1002\/JCSM.12639","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"4408_CR134","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/MUS.23539","volume":"47","author":"KM Attie","year":"2013","unstructured":"Attie KM, Borgstein NG, Yang Y et al (2013) A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve 47:416\u2013423. https:\/\/doi.org\/10.1002\/MUS.23539","journal-title":"Muscle Nerve"},{"key":"4408_CR135","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2020.20836","volume":"3","author":"D Rooks","year":"2020","unstructured":"Rooks D, Swan T, Goswami B et al (2020) Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open 3:e2020836. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2020.20836","journal-title":"JAMA Netw Open"},{"key":"4408_CR136","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/DOM.13042","volume":"20","author":"T Garito","year":"2018","unstructured":"Garito T, Roubenoff R, Hompesch M et al (2018) Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metab 20:94\u2013102. https:\/\/doi.org\/10.1111\/DOM.13042","journal-title":"Diabetes Obes Metab"},{"key":"4408_CR137","doi-asserted-by":"publisher","first-page":"E1967","DOI":"10.1210\/JC.2014-1271","volume":"99","author":"D Padhi","year":"2014","unstructured":"Padhi D, Higano CS, Shore ND et al (2014) Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 99:E1967\u2013E1975. https:\/\/doi.org\/10.1210\/JC.2014-1271","journal-title":"J Clin Endocrinol Metab"},{"key":"4408_CR138","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1172\/JCI13562","volume":"109","author":"AC McPherron","year":"2002","unstructured":"McPherron AC, Lee S-J (2002) Suppression of body fat accumulation in myostatin-deficient mice. J Clin Invest 109:595\u2013601. https:\/\/doi.org\/10.1172\/JCI13562","journal-title":"J Clin Invest"},{"key":"4408_CR139","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/CTS.12420","volume":"9","author":"P Singh","year":"2016","unstructured":"Singh P, Rong H, Gordi T et al (2016) Translational pharmacokinetic\/pharmacodynamic analysis of MYO-029 antibody for muscular dystrophy. Clin Transl Sci 9:302\u2013310. https:\/\/doi.org\/10.1111\/CTS.12420","journal-title":"Clin Transl Sci"},{"key":"4408_CR140","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1210\/ME.2010-0127","volume":"24","author":"SJ Lee","year":"2010","unstructured":"Lee SJ, Lee YS, Zimmers TA et al (2010) Regulation of muscle mass by follistatin and activins. Mol Endocrinol 24:1998. https:\/\/doi.org\/10.1210\/ME.2010-0127","journal-title":"Mol Endocrinol"},{"key":"4408_CR141","doi-asserted-by":"publisher","DOI":"10.1172\/JCI148372","author":"SJ Lee","year":"2021","unstructured":"Lee SJ (2021) Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction. J Clin Investig. https:\/\/doi.org\/10.1172\/JCI148372","journal-title":"J Clin Investig"},{"key":"4408_CR142","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/10915818211025477","volume":"40","author":"BT Welsh","year":"2021","unstructured":"Welsh BT, Cote SM, Meshulam D et al (2021) Preclinical safety assessment and toxicokinetics of apitegromab, an antibody targeting proforms of myostatin for the treatment of muscle-atrophying disease. Int J Toxicol 40:322\u2013336. https:\/\/doi.org\/10.1177\/10915818211025477","journal-title":"Int J Toxicol"},{"key":"4408_CR143","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/CEN.13601","volume":"88","author":"T Garito","year":"2018","unstructured":"Garito T, Zakaria M, Papanicolaou DA et al (2018) Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf) 88:908\u2013919. https:\/\/doi.org\/10.1111\/CEN.13601","journal-title":"Clin Endocrinol (Oxf)"},{"key":"4408_CR144","doi-asserted-by":"publisher","DOI":"10.1210\/ENDOCR\/BQAA056","author":"G Schang","year":"2020","unstructured":"Schang G, Ongaro L, Schultz H et al (2020) Murine FSH production depends on the activin type II receptors ACVR2A and ACVR2B. Endocrinology. https:\/\/doi.org\/10.1210\/ENDOCR\/BQAA056","journal-title":"Endocrinology"},{"key":"4408_CR145","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/FNAGI.2015.00013\/BIBTEX","volume":"7","author":"S Krause","year":"2015","unstructured":"Krause S (2015) Insights into muscle degeneration from heritable inclusion body myopathies. Front Aging Neurosc 7:13. https:\/\/doi.org\/10.3389\/FNAGI.2015.00013\/BIBTEX","journal-title":"Front Aging Neurosc"},{"key":"4408_CR146","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/S11357-011-9327-0","volume":"35","author":"N Garatachea","year":"2013","unstructured":"Garatachea N, Luc\u00eda A (2013) Genes and the ageing muscle: a review on genetic association studies. Age (Dordr) 35:207\u2013233. https:\/\/doi.org\/10.1007\/S11357-011-9327-0","journal-title":"Age (Dordr)"},{"key":"4408_CR147","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/nn1876","volume":"10","author":"M Nagai","year":"2007","unstructured":"Nagai M, Re DB, Nagata T et al (2007) Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 10:615\u2013622. https:\/\/doi.org\/10.1038\/nn1876","journal-title":"Nat Neurosci"},{"key":"4408_CR148","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/NBT.1957","volume":"29","author":"AM Haidet-Phillips","year":"2011","unstructured":"Haidet-Phillips AM, Hester ME, Miranda CJ et al (2011) Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 29:824. https:\/\/doi.org\/10.1038\/NBT.1957","journal-title":"Nat Biotechnol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04408-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04408-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T09:20:47Z","timestamp":1659604847000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04408-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":148,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["4408"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04408-w","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no existing conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"374"}}